Assessment of palliative care in lung cancer in Turkey

dc.contributor.buuauthorErol, Mehmet Muharrem
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.tr_TR
dc.contributor.researcheridCPM-5715-2022tr_TR
dc.contributor.scopusid35605916500tr_TR
dc.date.accessioned2023-09-24T13:01:20Z
dc.date.available2023-09-24T13:01:20Z
dc.date.issued2017
dc.descriptionÇalışmada 43 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.tr_TR
dc.description.abstractObjective: To investigate the symptoms of lung cancer in Turkey and to evaluate approaches to alleviate these symptoms. Subjects and Methods: This study included 1,245 lung cancer patients from 26 centers in Turkey. Demographic characteristics as well as information regarding the disease and treatments were obtained from medical records and patient interviews. Symptoms were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and were graded on a scale between 0 and 10 points. Data were compared using the. 2, Student t, and Mann-Whitney U tests. Potential predictors of symptoms were analyzed using logistic regression analysis. Results: The most common symptom was tiredness (n = 1,002; 82.1%), followed by dyspnea (n = 845; 69.3%), appetite loss (n = 801; 65.7%), pain (n = 798; 65.4%), drowsiness (n = 742; 60.8%), anxiety (n = 704; 57.7%), depression (n = 623; 51.1%), and nausea (n = 557; 45.5%). Of the 1,245 patients, 590 (48.4%) had difficulty in initiating or maintaining sleep. The symptoms were more severe in stages III and IV. Logistic regression analysis indicated a clear association between demographic characteristics and symptom distress, as well as between symptom distress (except nausea) and well-being. Overall, 804 (65.4%) patients used analgesics, 630 (51.5%) received treatment for dyspnea, 242 (19.8%) used enteral/parenteral nutrition, 132 (10.8%) used appetite stimulants, and 129 (10.6%) used anxiolytics/antidepressants. Of the 799 patients who received analgesics, 173 (21.7%) reported that their symptoms were under control, and also those on other various treatment modalities (dyspnea: 78/627 [12.4%], appetite stimulant: 25/132 [18.9%], and anxiolytics/antidepressants: 25/129 [19.4%]) reported that their symptoms were controlled. Conclusion: In this study, the symptoms progressed and became more severe in the advanced stages of lung cancer, and palliative treatment was insufficient in most of the patients in Turkey.en_US
dc.identifier.citationBülbül, Y. vd. (2017). ''Assessment of palliative care in lung cancer in Turkey''. Medical Principles and Practice, 26(1), 50-56.en_US
dc.identifier.endpage56tr_TR
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue1tr_TR
dc.identifier.pubmed27780164tr_TR
dc.identifier.scopus2-s2.0-84992688577tr_TR
dc.identifier.startpage50tr_TR
dc.identifier.urihttps://doi.org/10.1159/000452801
dc.identifier.urihttps://karger.com/mpp/article/26/1/50/207403/Assessment-of-Palliative-Care-in-Lung-Cancer-in
dc.identifier.urihttp://hdl.handle.net/11452/33997
dc.identifier.volume26tr_TR
dc.identifier.wos000391457100008tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalMedical Principles and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGeneral &iInternal medicineen_US
dc.subjectLung canceren_US
dc.subjectPalliationen_US
dc.subjectPalliative treatmenten_US
dc.subjectSymptomsen_US
dc.subjectTreatmenten_US
dc.subjectQuality-of-lifeen_US
dc.subjectSleep disturbancesen_US
dc.subjectSymptom experienceen_US
dc.subjectSupportive careen_US
dc.subjectPainen_US
dc.subjectChemotherapyen_US
dc.subjectPrevalenceen_US
dc.subjectImpacten_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeAnxiolytic agenten_US
dc.subject.emtreeAppetite stimulanten_US
dc.subject.emtreeBisphosphonic acid derivativeen_US
dc.subject.emtreeBronchodilating agenten_US
dc.subject.emtreeCyproheptadineen_US
dc.subject.emtreeFentanylen_US
dc.subject.emtreeMegestrol acetateen_US
dc.subject.emtreeMorphineen_US
dc.subject.emtreeNonsteroid antiinflammatory agenten_US
dc.subject.emtreeParacetamolen_US
dc.subject.emtreeSedative agenten_US
dc.subject.emtreeTramadolen_US
dc.subject.emtreeVitaminen_US
dc.subject.emtreeAnalgesic agenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAnalgesiaen_US
dc.subject.emtreeAnxiety disorderen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone metastasisen_US
dc.subject.emtreeCachexiaen_US
dc.subject.emtreeCancer fatigueen_US
dc.subject.emtreeCancer painen_US
dc.subject.emtreeCancer palliative therapyen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeCombination drug therapyen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDepressionen_US
dc.subject.emtreeDrowsinessen_US
dc.subject.emtreeDysphagiaen_US
dc.subject.emtreeDyspneaen_US
dc.subject.emtreeEdmonton symptom assessment scaleen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLoss of appetiteen_US
dc.subject.emtreeLung canceren_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeNasogastric tubeen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeNebulizeren_US
dc.subject.emtreeNoninvasive ventilationen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeNutritional supporten_US
dc.subject.emtreeOxygen therapyen_US
dc.subject.emtreePain severityen_US
dc.subject.emtreeParenteral nutritionen_US
dc.subject.emtreePercutaneous endoscopic gastrostomyen_US
dc.subject.emtreePleurodesisen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreePsychopharmacotherapyen_US
dc.subject.emtreeSleep disorderen_US
dc.subject.emtreeStenten_US
dc.subject.emtreeSymptom assessmenten_US
dc.subject.emtreeThoracocentesisen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeVitamin supplementationen_US
dc.subject.emtreeWellbeingen_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeComplicationen_US
dc.subject.emtreeDyspneaen_US
dc.subject.emtreeFatigueen_US
dc.subject.emtreeInterviewen_US
dc.subject.emtreeLung neoplasmsen_US
dc.subject.emtreePainen_US
dc.subject.emtreePalliative therapyen_US
dc.subject.emtreePsychologyen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeSquamous cell carcinomaen_US
dc.subject.emtreeStatistical modelen_US
dc.subject.emtreeTurkeyen_US
dc.subject.emtreeComorbidityen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAnalgesicsen_US
dc.subject.meshComorbidityen_US
dc.subject.meshDyspneaen_US
dc.subject.meshFatigueen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInterviews as topicen_US
dc.subject.meshLogistic modelsen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshNeoplasmsen_US
dc.subject.meshSquamous cellen_US
dc.subject.meshPainen_US
dc.subject.meshPalliative careen_US
dc.subject.meshQuality of Lifeen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusChildhood Cancer Survivor; Sleep Disorders; Breast Neoplasmsen_US
dc.subject.wosMedicine, general & internalen_US
dc.titleAssessment of palliative care in lung cancer in Turkeyen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Erol_vd_2017.pdf
Size:
158.03 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: